Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Xenon Pharmaceuticals Inc.

XENE · Nasdaq · CIK 0001582313 · Healthcare · Biotechnology

INSIDER SIGNAL

51.5 / 100

2 buyers · 2 purchase transaction lines · $1.7M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyModerate
ConvictionLow
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+14.2 / 25
Role+13.0 / 20
Recency+7.4 / 10
Conviction+2.9 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: PRESIDENT & CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Recent activity · latest purchase 2026-09-30

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
GANNON STEVENDirector
○○○▼
Svoronos DawnDirector
○○○
PATOU GARYDirector
○▼
Cannon GillianDirector
○▼
Kelly Thomas PatrickChief Financial Officer
●○
Machado PatrickDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION67%Largest buyer: MORTIMER IAN · $1.1M
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-09-30–2026-09-30

Roles in the peak window: Chief Financial Officer, PRESIDENT & CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

51.5 / 100

Latest recorded score

↓ -0.3 ptsversus the previous recorded snapshot
  1. 52.4
  2. 52.2
  3. 52.0
  4. 51.8
  5. 51.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
26Sales
23Other Form 4 lines
25SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING5 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-38.0%
3M
-46.2%
6M
-37.6%
12M
-7.2%

Volatility & liquidity

Volatility
57.1%
Beta
—
Avg daily value
USD 51.6M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-59.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
6,041,487
Previous report
6,444,815
Avg daily volume
3,834,835
Days to cover
1.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-30MORTIMER IANPurchase (P)Common Shares30,000USD 37.38USD 1,121,400SEC filing ↗
2026-09-30Kelly Thomas PatrickPurchase (P)Common Shares15,000USD 37.32USD 559,740SEC filing ↗
2022-01-21KENNEY CHRISTOPHER JOHNPurchase (P)Common Shares700USD 28.81USD 20,167SEC filing ↗
2021-12-06Von Seggern ChristopherPurchase (P)Common Shares4,000USD 24.40USD 97,600SEC filing ↗

Form 4 evidence

51 transaction lines in the latest 365-day window; 241 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-15Kelly Thomas PatrickOption exercise / conversion (M)Common Shares7,500USD —USD —SEC filing ↗
2026-09-30MORTIMER IANPurchase (P)Common Shares30,000USD 37.38USD 1,121,400SEC filing ↗
2026-09-30Kelly Thomas PatrickPurchase (P)Common Shares15,000USD 37.32USD 559,740SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-15Kelly Thomas PatrickOption exercise / conversion (M)Common Shares7,500USD —USD —SEC filing ↗
2026-09-30MORTIMER IANPurchase (P)Common Shares30,000USD 37.38USD 1,121,400SEC filing ↗
2026-09-30Kelly Thomas PatrickPurchase (P)Common Shares15,000USD 37.32USD 559,740SEC filing ↗
2026-09-01Svoronos DawnOption exercise / conversion (M)Common Shares5,144USD 8.15USD 41,924SEC filing ↗
2026-08-28KENNEY CHRISTOPHER JOHNSale (S)Common Shares7,068USD 60.25USD 425,849SEC filing ↗
2026-08-11GANNON STEVENSale (S)Common Shares10,000USD 64.06USD 640,600SEC filing ↗
2026-06-05PATOU GARYSale (S)Common Shares1,322USD 53.14USD 70,251SEC filing ↗
2026-06-05Cannon GillianSale (S)Common Shares1,190USD 53.14USD 63,237SEC filing ↗
2026-06-01Svoronos DawnOption exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01Svoronos DawnTax withholding (F)Common Shares1,416USD 53.41USD 75,629SEC filing ↗
2026-06-01PATOU GARYOption exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01Machado PatrickOption exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01Gover Justin D.Option exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01GAROFALO ELIZABETH A.Option exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01GANNON STEVENOption exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-06-01GANNON STEVENTax withholding (F)Common Shares1,416USD 53.41USD 75,629SEC filing ↗
2026-06-01Cannon GillianOption exercise / conversion (M)Common Shares2,645USD —USD —SEC filing ↗
2026-05-12GANNON STEVENOption exercise / conversion (M)Common Shares3,500USD 7.38USD 25,830SEC filing ↗
2026-03-13MORTIMER IANSale (S)Common Shares7,308USD 55.23USD 403,621SEC filing ↗
2026-03-13KENNEY CHRISTOPHER JOHNSale (S)Common Shares1,410USD 55.23USD 77,874SEC filing ↗
2026-03-13DiFabio AndreaSale (S)Common Shares1,342USD 55.23USD 74,119SEC filing ↗
2026-03-12MORTIMER IANOption exercise / conversion (M)Common Shares12,500USD —USD —SEC filing ↗
2026-03-12KENNEY CHRISTOPHER JOHNOption exercise / conversion (M)Common Shares3,750USD —USD —SEC filing ↗
2026-03-12DiFabio AndreaOption exercise / conversion (M)Common Shares3,750USD —USD —SEC filing ↗
2026-03-10MORTIMER IANSale (S)Common Shares11,269USD 60.11USD 677,380SEC filing ↗
2026-03-10KENNEY CHRISTOPHER JOHNSale (S)Common Shares2,771USD 60.11USD 166,565SEC filing ↗
2026-03-10DiFabio AndreaSale (S)Common Shares2,607USD 60.11USD 156,707SEC filing ↗
2026-03-09MORTIMER IANSale (S)Common Shares270,000USD 60.33USD 16,289,142SEC filing ↗
2026-03-09MORTIMER IANOption exercise / conversion (M)Common Shares290,000USD —USD —SEC filing ↗
2026-03-09KENNEY CHRISTOPHER JOHNOption exercise / conversion (M)Common Shares7,500USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerXENE
CIK0001582313
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history241 transaction lines from 2020-05-26 to 2026-10-15
4 P purchase lines · 106 S sale lines · 131 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.